Wednesday, September 30, 2020

AcelRx Pharmaceuticals Inc. [ACRX] moved up 17.76: Why It’s Important

Must read

Market Analysts see Spectrum Pharmaceuticals Inc. [SPPI] gaining to $12. Time to buy?

Spectrum Pharmaceuticals Inc. price plunged by -4.30 percent to reach at -$0.19. A sum of 2651802 shares traded at recent session while its...

Etsy Inc. [ETSY] stock Upgrade by BTIG Research analyst, price target now $138

Etsy Inc. price surged by 4.05 percent to reach at $4.6. A sum of 2567392 shares traded at recent session while its average...

Clear Channel Outdoor Holdings Inc. [CCO] is -67.40% lower this YTD. Is it still time to buy?

Clear Channel Outdoor Holdings Inc. plunged by -$0.05 during the normal trading session on Thursday and reaching a high of $0.97 during the...

Varian Medical Systems Inc. [VAR] Is Currently -0.40 below its 200 Period Moving Avg: What Dose This Mean?

Varian Medical Systems Inc. plunged by -$0.69 during the normal trading session on Wednesday and reaching a high of $172.80 during the day...

AcelRx Pharmaceuticals Inc. [NASDAQ: ACRX] closed the trading session at $1.26 on 09/14/20. The day’s price range saw the stock hit a low of $1.1128, while the highest price level was $1.29. The company report on September 14, 2020 that AcelRx Announces DSUVIA® Added to the U.S. Department of Defense’s Joint Deployment Formulary.

DSUVIA now available to all branches of the military.

Availability expanded beyond Milestone C approval for Army sets, kits and outfits.

The stocks have a year to date performance of -40.28 percent and weekly performance of 9.57 percent. The stock has been moved at 50.02 percent over the last six months. The stock has performed 1.61 percent around the most recent 30 days and changed -5.26 percent over the most recent 3-months.

If compared to the average trading volume of 1.09M shares, ACRX reached to a volume of 2273773 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about AcelRx Pharmaceuticals Inc. [ACRX]:

Credit Suisse have made an estimate for AcelRx Pharmaceuticals Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on July 20, 2020. While these analysts kept the previous recommendation, Credit Suisse dropped their target price from $7 to $2. The new note on the price target was released on November 11, 2019, representing the official price target for AcelRx Pharmaceuticals Inc. stock.

The Average True Range (ATR) for AcelRx Pharmaceuticals Inc. is set at 0.10, with the Price to Sales ratio for ACRX stock in the period of the last 12 months amounting to 26.36.

ACRX stock trade performance evaluation

AcelRx Pharmaceuticals Inc. [ACRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.57. With this latest performance, ACRX shares gained by 1.61% in over the last four-week period, additionally plugging by 50.02% over the last 6 months – not to mention a drop of -50.59% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRX stock in for the last two-week period is set at 54.85, with the RSI for the last a single of trading hit 57.71, and the three-weeks RSI is set at 52.40 for AcelRx Pharmaceuticals Inc. [ACRX]. The present Moving Average for the last 50 days of trading for this stock 1.1819, while it was recorded at 1.1360 for the last single week of trading, and 1.4595 for the last 200 days.

AcelRx Pharmaceuticals Inc. [ACRX]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and AcelRx Pharmaceuticals Inc. [ACRX] shares currently have an operating margin of -2368.06 and a Gross Margin at -197.34. AcelRx Pharmaceuticals Inc.’s Net Margin is presently recorded at -2325.91.

Return on Total Capital for ACRX is now -56.97, given the latest momentum, and Return on Invested Capital for the company is -60.73. Additionally, ACRX Total Debt to Total Capital is recorded at 151.53, with Total Debt to Total Assets ending up at 133.32.

Reflecting on the efficiency of the workforce at the company, AcelRx Pharmaceuticals Inc. [ACRX] managed to generate an average of -$537,778 per employee. Receivables Turnover for the company is 4.58 with a Total Asset Turnover recorded at a value of 0.02.AcelRx Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 3.00.

Earnings per share (EPS) analysis for AcelRx Pharmaceuticals Inc. [ACRX] stock

With the latest financial reports released by the company, AcelRx Pharmaceuticals Inc. posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 27.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACRX.

AcelRx Pharmaceuticals Inc. [ACRX]: Insider Ownership positions

There are presently around $22 million, or 20.30% of ACRX stock, in the hands of institutional investors. The top three institutional holders of ACRX stocks are: BLACKROCK INC. with ownership of 5,509,735, which is approximately -2.651% of the company’s market cap and around 1.10% of the total institutional ownership; VANGUARD GROUP INC, holding 3,722,340 shares of the stock with an approximate value of $4.69 million in ACRX stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $1.58 million in ACRX stock with ownership of nearly 8.559% of the company’s market capitalization.

Positions in AcelRx Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 33 institutional holders increased their position in AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] by around 1,440,853 shares. Additionally, 29 investors decreased positions by around 2,527,749 shares, while 19 investors held positions by with 13,610,672 shares. The mentioned changes placed institutional holdings at 17,579,274 shares, according to the latest SEC report filing. ACRX stock had 14 new institutional investments in for a total of 411,938 shares, while 7 institutional investors sold positions of 80,721 shares during the same period.

More articles


Please enter your comment!
Please enter your name here

Latest article

Lake Street Initiated Checkpoint Therapeutics Inc. [CKPT]. What else is Wall St. saying?

Checkpoint Therapeutics Inc. gained 6.49% on the last trading session, reaching $2.79 price per share at the time. Checkpoint Therapeutics Inc. represents 51.80...

Colliers Securities slashes price target on Avaya Holdings Corp. [AVYA] – find out why.

Avaya Holdings Corp. surged by $0.94 during the normal trading session on Tuesday and reaching a high of $15.20 during the day while...

Evercore ISI lifts Spero Therapeutics Inc. [SPRO] price estimate. Who else is bullish?

Spero Therapeutics Inc. traded at a high on 09/29/20, posting a 6.99 gain after which it closed the day’ session at $9.95. The...

American Superconductor Corporation [AMSC] is 104.20% higher this YTD. Is it still time to buy?

American Superconductor Corporation price surged by 7.08 percent to reach at $1.06. A sum of 2043887 shares traded at recent session while its...

For Seres Therapeutics Inc. [MCRB], Chardan Capital Markets sees a drop to $27.50. What next?

Seres Therapeutics Inc. gained 7.28% or 1.95 points to close at $28.74 with a heavy trading volume of 1021239 shares. It opened the...